EktoTherix: Initial clinical evaluation of a regenerative tissue scaffold for repair of surgical excision wounds

EktoTherix：用于修复手术切除伤口的再生组织支架的初步临床评估

• 批准号: 101108
• 金额: $ 25.92万
• 依托单位: NEOTHERIX LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2012
• 资助国家: 英国
• 起止时间: 2012 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=101108
• 关键词: EktoTherix; Initial; clinical; evaluation; regenerative

Neotherix (York UK) has developed the EktoTherix™ bioresorbable scaffold material that assists patient tissue repair and regeneration, with an initial target clinical application of non-melanoma skin cancers (NMSC) with further indications to follow. A patch of the material is used following excision of the basal or squamous carcinoma by the clinician, and this rapidly allows the wound space to be filled with (and then covered by) the patients’ own skin cells. This TSB funded project will continue the development of the product towards full commercialisation, with further development of the product registration package leading to a clinical evaluation involving a small number of patients. The team will also complete a health economics evaluation prior to launching the product within the UK and EU market in 2013/2014. The estimated global market for this product for NMSC alone is £867m pa.

Neotherix（英国约克）开发了 EktoTherix™ 生物可吸收支架材料，可帮助患者组织修复和再生，初步目标是非黑色素瘤皮肤癌 (NMSC) 的临床应用，并有后续适应症。临床医生在切除基底癌或鳞状癌后使用一块材料，这可以迅速使伤口空间充满（然后被患者自身的皮肤细胞覆盖）。该 TSB 资助的项目将继续开发该产品，以实现全面商业化，并进一步开发产品注册包，从而进行涉及少数患者的临床评估。该团队还将在 2013/2014 年在英国和欧盟市场推出该产品之前完成健康经济学评估。仅 NMSC 的该产品的全球市场估计就达到每年 8.67 亿英镑。